MedElevator
Войти в исследования Annals of hepatology · 2026
Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osman Mohamad Mahdi, Sims Omar T, Chiang Dian J
Аннотация
INTRODUCTION AND OBJECTIVES: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i1) improve cardiovascular and renal outcomes in type 2 diabetes mellitus, but their safety and clinical impact in advanced liver disease remain uncertain because patients with cirrhosis were underrepresented in major trials.
MATERIALS AND METHODS: Using the TriNetX research network, we identified adults with alcoholic cirrhosis, type 2 diabetes, and obesity and compared outcomes according to SGLT2-i exposure. After 1:1 propensity score matching, 5,128 matched pairs were analyzed. The primary outcome was all-cause mortality; secondary outcomes included all-cause hospitalization, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and variceal bleeding.
RESULTS: In the matched cohort, SGLT2-i use was associated with lower all-cause mortality (HR, 0.71; 95% CI, 0.66 to 0.78), hospitalization (HR, 0.84; 95% CI, 0.80 to 0.89), ascites (HR, 0.72; 95% CI, 0.67 to 0.77), spontaneous bacterial peritonitis (HR, 0.74; 95% CI, 0.62 to 0.87), and variceal bleeding (HR, 0.82; 95% CI, 0.67 to 0.99), with no difference in hepatic encephalopathy.
CONCLUSIONS: Among patients with alcoholic cirrhosis, type 2 diabetes, and obesity, SGLT2-i use was associated with improved survival and fewer liver-related complications.
MATERIALS AND METHODS: Using the TriNetX research network, we identified adults with alcoholic cirrhosis, type 2 diabetes, and obesity and compared outcomes according to SGLT2-i exposure. After 1:1 propensity score matching, 5,128 matched pairs were analyzed. The primary outcome was all-cause mortality; secondary outcomes included all-cause hospitalization, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and variceal bleeding.
RESULTS: In the matched cohort, SGLT2-i use was associated with lower all-cause mortality (HR, 0.71; 95% CI, 0.66 to 0.78), hospitalization (HR, 0.84; 95% CI, 0.80 to 0.89), ascites (HR, 0.72; 95% CI, 0.67 to 0.77), spontaneous bacterial peritonitis (HR, 0.74; 95% CI, 0.62 to 0.87), and variceal bleeding (HR, 0.82; 95% CI, 0.67 to 0.99), with no difference in hepatic encephalopathy.
CONCLUSIONS: Among patients with alcoholic cirrhosis, type 2 diabetes, and obesity, SGLT2-i use was associated with improved survival and fewer liver-related complications.